AstraZeneca pays $50 million for rights to Merck cancer drug

Capitainer plays a key role in the international AIR project (Artificial Intelligence Radiology) aimed at improving the diagnostics and monitoring of lung diseases.

Danish and Swedish life science strategies under the lens at Medicon Valley Alliance Annual Meeting.

NordForsk has decided to fund six Nordic research networks that will apply for EU calls in the field of antimicrobial resistance (AMR).

The company has announced the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden to complete initial investigations on the effect of Pila Pharma's lead molecule, XEN-D0501, on Abdominal Aorta Aneurism growth in mice.

Medivir has announced a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox in combination with lenvatinib mesylate in a randomized, phase 2b study in second-line advanced liver cancer patients.

NEOGAP Therapeutics has entered a strategic collaboration with NorthX Biologics to advance manufacturing strategies for NEOGAP’s personalized cancer cell therapy.

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.